Q1 EPS Estimates for Sanara MedTech Reduced by HC Wainwright

Sanara MedTech Inc. (NASDAQ:SMTI) – Research analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Sanara MedTech in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.31) for the quarter, down from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $51.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.12) EPS.

Sanara MedTech (NASDAQ:SMTI) last issued its earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. The business had revenue of $26.31 million for the quarter, compared to the consensus estimate of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $46.00 target price on shares of Sanara MedTech in a research note on Wednesday.

Sanara MedTech Trading Down 3.3 %

Shares of NASDAQ:SMTI opened at $30.19 on Friday. Sanara MedTech has a 1 year low of $26.00 and a 1 year high of $39.08. The stock’s fifty day moving average price is $34.26 and its 200-day moving average price is $33.74. The company has a market cap of $268.75 million, a P/E ratio of -30.49 and a beta of 1.37. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02.

Institutional Investors Weigh In On Sanara MedTech

Hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its stake in shares of Sanara MedTech by 53.9% in the 4th quarter. Wells Fargo & Company MN now owns 1,893 shares of the company’s stock worth $63,000 after buying an additional 663 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Sanara MedTech in the fourth quarter valued at about $106,000. Deutsche Bank AG boosted its position in Sanara MedTech by 75.4% in the fourth quarter. Deutsche Bank AG now owns 3,547 shares of the company’s stock worth $118,000 after purchasing an additional 1,525 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Sanara MedTech by 127.2% in the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock worth $123,000 after purchasing an additional 2,272 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Sanara MedTech by 38.7% during the 4th quarter. Bank of America Corp DE now owns 3,778 shares of the company’s stock valued at $125,000 after purchasing an additional 1,055 shares during the period. 8.10% of the stock is currently owned by hedge funds and other institutional investors.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.